Sheet 1 of 1

FORM PTO-1449		US Dept. Of Commerces Patent and Trace HAD Office		ATTORNEY DOCKET NO.		SERIAL NO.		
Tutone and Transpare Office				4121-122		09/834,291		
				APPLICANT			HE(	FIVE
NFORM	ATION D	SISCLOSURE ST	<b>FATEMENT</b>	VD AND COD				-104
(use several sheets if necessary)				KRAMMER, et al. FILING DATE		99/834,291 RECEIVE MAY 2 9 200 GROUP TECH CENTER 1600		
				TIBING BITTE		TECHOTAL		
				April 12, 2001		1646	CH CEN	TER 1600
XAMINE	T	PATENT	U.S.	PATENT DOCUMENTS	<del></del>			
R INITIAL		NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
			FOREL	CALDATENT DOCUMEN	TC			
		DOCUMENT	PUBLICATION	GN PATENT DOCUMEN'	18		TRANSI	LATION
		NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
Nl	AA	WO 98/08965	5 March 1998	PCT		"		
AS	AB	0 518 650	10 June 1992	Europe				
08	AC	WO 95/19367	20 July 1995	PCT				
		OTUED DOCI	IMENTS (Include	ling Author Title Journal	Data Basa N	[marken E4e]		
DR.	AD	OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)  Behrmann, et al., "Structure of the human APO-1 gene." Eur. J. Immunol. 1994. 24: p. 3057-3062.						
u x 🔪		XP 000572417. Chan & Owen Schaub, "Identification and analysis of A p53 binding element within the promoter of the FAS/APO-1 (CD95) gene,"						
05	AE √				ilialysis of A p	on omanig or	micht with.	in the
DS NX	AE J	promoter of the XP-000906792	FAS/APO-1 (CL . Muller et al., "p	095) gene," 053 activates the CD95 (APC	D-1/FAS) gene			
D D D		promoter of the XP-000906792 anticancer drug XP-000906826	FAS/APO-1 (CI . Muller et al., "p s," J. Exp. Med. . Rudert et al., "I	095) gene,"	D-1/FAS) gene 2033-2045. nhancer, and b	in response to	o DNA dan	nage by
os Os Os	AF	promoter of the XP-000906792 anticancer drug XP-000906826	FAS/APO-1 (CI . Muller et al., "p s," J. Exp. Med. . Rudert et al., "I	095) gene," 053 activates the CD95 (APC 1998: Vol. 188, No. 11. p. 2 dentification of a silencer, er	D-1/FAS) gene 2033-2045. nhancer, and b	in response to	o DNA dan	nage by
D D D	AF	promoter of the XP-000906792 anticancer drug XP-000906826	FAS/APO-1 (CI . Muller et al., "p s," J. Exp. Med. . Rudert et al., "I	095) gene," 053 activates the CD95 (APC 1998: Vol. 188, No. 11. p. 2 dentification of a silencer, er	D-1/FAS) gene 2033-2045. nhancer, and b	in response to	o DNA dan	nage by
os os os os os	AF	promoter of the XP-000906792 anticancer drug XP-000906826	FAS/APO-1 (CI . Muller et al., "p s," J. Exp. Med. . Rudert et al., "I	095) gene," 053 activates the CD95 (APC 1998: Vol. 188, No. 11. p. 2 dentification of a silencer, er	D-1/FAS) gene 2033-2045. nhancer, and b	in response to	o DNA dan	nage by
DS PS PS	AF	promoter of the XP-000906792 anticancer drug XP-000906826	FAS/APO-1 (CI . Muller et al., "p s," J. Exp. Med. . Rudert et al., "I	095) gene," 053 activates the CD95 (APC 1998: Vol. 188, No. 11. p. 2 dentification of a silencer, er	D-1/FAS) gene 2033-2045. nhancer, and b 5: Vol. 14, No	asal promoter . 11, p. 931-93	o DNA dan	nage by
DS PS PS NAMINI	AF AG	promoter of the XP-000906792 anticancer drug XP-000906826	FAS/APO-1 (CI . Muller et al., "p s," J. Exp. Med. . Rudert et al., "I	095) gene," 053 activates the CD95 (APC 1998: Vol. 188, No. 11. p. 2 dentification of a silencer, er	D-1/FAS) gene 2033-2045. nhancer, and b 5: Vol. 14, No	in response to asal promoter . 11, p. 931-93	o DNA dan	nage by